Invention Grant
- Patent Title: Methods of reducing levels of tau
-
Application No.: US14020776Application Date: 2013-09-06
-
Publication No.: US09696306B2Publication Date: 2017-07-04
- Inventor: Tae-Wan Kim , Laura Beth Johnson McIntire , Natalie Landman , Gina Finan
- Applicant: The Trustees of Columbia University in the City of New York
- Applicant Address: US NY New York
- Assignee: The Trustees of Columbia University in the City of New York
- Current Assignee: The Trustees of Columbia University in the City of New York
- Current Assignee Address: US NY New York
- Agency: Baker Botts L.L.P.
- Main IPC: A61K31/137
- IPC: A61K31/137 ; A61K31/03 ; A61K31/085 ; G01N33/569 ; C12N5/0793 ; G01N33/50 ; A61K31/01 ; A61K31/145 ; A61K31/15 ; A61K31/41 ; A61K31/473 ; A61K31/5375 ; A61K31/7048

Abstract:
Successful CNS drug discovery requires a scalable, highly physiological neuronal model. Using directed differentiation of mouse embryonic stem (mES) cells, including mES cells isolated from a mouse model of Alzheimer's disease (AD), a highly homogeneous primary neuronal model amenable to phenotypic assays for production and synaptotoxicity of amyloid β-peptide was developed. This model furnishes a highly physiological and AD-relevant platform suitable for high throughput small molecule and functional genetic screens, providing specific small molecule compounds identified by such screens.
Public/Granted literature
- US20140171380A1 Screening Assays Using Stem Cells and Stem Cell-Derived Neurons from Mouse Models of Alzheimer's Disease Public/Granted day:2014-06-19
Information query